Tilray Inc (NASDAQ:TLRY) Director Sells $607,218.75 in Stock

Tilray Inc (NASDAQ:TLRY) Director Michael Auerbach sold 31,875 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $19.05, for a total value of $607,218.75. Following the sale, the director now owns 31,875 shares in the company, valued at approximately $607,218.75. The sale was disclosed in a filing with the SEC, which is available through this link.

NASDAQ:TLRY traded down $0.79 on Wednesday, hitting $18.76. The stock had a trading volume of 1,333,823 shares, compared to its average volume of 1,925,647. The business’s fifty day moving average is $21.60 and its 200 day moving average is $33.35. The company has a market cap of $1.89 billion, a PE ratio of -22.88 and a beta of 4.07. The company has a quick ratio of 1.69, a current ratio of 2.54 and a debt-to-equity ratio of 1.05. Tilray Inc has a 52 week low of $18.50 and a 52 week high of $106.00.

Tilray (NASDAQ:TLRY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.05). The firm had revenue of $51.10 million during the quarter, compared to the consensus estimate of $49.57 million. Tilray had a negative return on equity of 40.30% and a negative net margin of 97.39%. The firm’s revenue was up 411.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) EPS. Equities analysts predict that Tilray Inc will post -1.33 earnings per share for the current fiscal year.

Several brokerages recently commented on TLRY. Northland Securities restated a “hold” rating on shares of Tilray in a research report on Wednesday, August 14th. Piper Jaffray Companies cut their target price on Tilray from $72.00 to $31.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Stifel Nicolaus restated a “hold” rating on shares of Tilray in a research report on Wednesday, August 14th. ValuEngine upgraded Tilray from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Finally, Cantor Fitzgerald began coverage on Tilray in a research report on Monday, November 4th. They set a “neutral” rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company. Tilray currently has an average rating of “Hold” and a consensus target price of $43.13.

A number of large investors have recently made changes to their positions in the business. ETF Managers Group LLC bought a new position in Tilray in the second quarter worth approximately $92,004,000. Morgan Stanley boosted its holdings in Tilray by 44.2% in the second quarter. Morgan Stanley now owns 330,527 shares of the company’s stock worth $15,390,000 after acquiring an additional 101,375 shares in the last quarter. Think Investments LP bought a new position in Tilray in the second quarter worth approximately $7,031,000. SG Americas Securities LLC bought a new position in Tilray in the third quarter worth approximately $3,556,000. Finally, Vanguard Group Inc. bought a new position in Tilray in the second quarter worth approximately $3,484,000. Institutional investors and hedge funds own 8.70% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Read More: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Insider Buying and Selling by Quarter for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.